How Syngene’s ‘first-time right’ process advanced a novel vascular calcification inhibitor API from Lab-scale to Tox-batch manufacturing successfully

Learn how Syngene supported a pharma company in developing and manufacturing lab-scale and later Tox batches of its target molecule through an improved synthesis route. All this while meeting chemical purity requirements of >98%.

Author

Latest Blogs

Scientists reviewing records on a tablet, process knowledge management

Tech transfer in CDMOs: avoiding the scale-up trap

Self-amplifying RNA vaccine vials and syringe representing mRNA-based therapeutics

Self-amplifying RNA: the next chapter in mRNA therapeutics

Laboratory glassware with green leaves illustrating green chemistry in pharmaceuticals.

Green chemistry principles for a sustainable future in pharma

Integrated drug discovery scientist analysing digital lab data

Integrated Drug Discovery: why expertise matters

Bispecific antibodies: engineering complexity into simplicity

3D molecular model showing protein-protein interaction with two large structures in brown and blue, and a smaller pink molecule bound to the blue region.

Integrated Expertise for Complex Modalities: Driving Innovation in Molecular Glue Discovery

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details